FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107580116> ?p ?o ?g. }

• W2107580116 endingPage "556" @default.
• W2107580116 startingPage "549" @default.
• W2107580116 abstract "Our results with concurrent biochemotherapy in patients with stage IV melanoma have been encouraging. Based on these data, we conducted a phase II study to determine the clinical and histological response rate to neoadjuvant concurrent biochemotherapy in patients with local-regional metastases of cutaneous melanoma (stage III). A total of 65 patients with biopsy-proven, measurable and potentially resectable local-regional disease (nodal, satellite/in-transit metastases and/or local recurrence) were treated with cisplatin 20 mg/m2 intravenously (i.v.) on days 1 to 4, vinblastine 1.5 mg/m2 i.v. on days 1 to 4, dacarbazine 800 mg/m2 i.v. on day 1 only, interleukin-2 9 MIU/m2 per day i.v. by 96 h continuous infusion on days 1 to 4, and interferon-cc2a 5 MU/m2 subcutaneously on days 1 to 5, repeated every 3 weeks. Patients underwent surgery after two to four courses of biochemotherapy. Those with tumour regression after two preoperative courses received two additional postoperative courses. Of the 64 patients assessable for clinical response, 28 (44%) had a partial response. Of the 62 patients whose response was assessed histologically, four (6.5%) had no evidence of viable tumour in the surgical specimen (pathological complete remission, pCR) and 27 (43.5%) had a partial response, giving an overall response rate of 50%. Tumour burden did not correlate with response, although patients who achieved a pCR had a significantly lower tumour burden (P = 0.02). Our phase II study indicates that neoadjuvant biochemotherapy is an active treatment for melanoma patients with local-regional metastases. However, it is unclear if biochemotherapy is more active than chemotherapy alone; phase III randomized trials are ongoing to answer this question in patients with stage IV disease. 1998 Lippincott Williams & Wilkins" @default.
• W2107580116 created "2016-06-24" @default.
• W2107580116 creator A5009965176 @default.
• W2107580116 creator A5013841368 @default.
• W2107580116 creator A5016215141 @default.
• W2107580116 creator A5022491856 @default.
• W2107580116 creator A5041570474 @default.
• W2107580116 creator A5042127830 @default.
• W2107580116 creator A5046099119 @default.
• W2107580116 creator A5058898270 @default.
• W2107580116 creator A5060563693 @default.
• W2107580116 creator A5070594639 @default.
• W2107580116 creator A5071770443 @default.
• W2107580116 creator A5076432829 @default.
• W2107580116 creator A5077015059 @default.
• W2107580116 creator A5078841756 @default.
• W2107580116 creator A5087385450 @default.
• W2107580116 date "1998-12-01" @default.
• W2107580116 modified "2023-09-24" @default.
• W2107580116 title "Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases" @default.
• W2107580116 doi "https://doi.org/10.1097/00008390-199812000-00010" @default.
• W2107580116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9918417" @default.
• W2107580116 hasPublicationYear "1998" @default.
• W2107580116 type Work @default.
• W2107580116 sameAs 2107580116 @default.
• W2107580116 citedByCount "72" @default.
• W2107580116 countsByYear W21075801162012 @default.
• W2107580116 countsByYear W21075801162013 @default.
• W2107580116 countsByYear W21075801162014 @default.
• W2107580116 countsByYear W21075801162015 @default.
• W2107580116 countsByYear W21075801162016 @default.
• W2107580116 countsByYear W21075801162017 @default.
• W2107580116 countsByYear W21075801162018 @default.
• W2107580116 countsByYear W21075801162019 @default.
• W2107580116 countsByYear W21075801162020 @default.
• W2107580116 countsByYear W21075801162021 @default.
• W2107580116 countsByYear W21075801162022 @default.
• W2107580116 countsByYear W21075801162023 @default.
• W2107580116 crossrefType "journal-article" @default.
• W2107580116 hasAuthorship W2107580116A5009965176 @default.
• W2107580116 hasAuthorship W2107580116A5013841368 @default.
• W2107580116 hasAuthorship W2107580116A5016215141 @default.
• W2107580116 hasAuthorship W2107580116A5022491856 @default.
• W2107580116 hasAuthorship W2107580116A5041570474 @default.
• W2107580116 hasAuthorship W2107580116A5042127830 @default.
• W2107580116 hasAuthorship W2107580116A5046099119 @default.
• W2107580116 hasAuthorship W2107580116A5058898270 @default.
• W2107580116 hasAuthorship W2107580116A5060563693 @default.
• W2107580116 hasAuthorship W2107580116A5070594639 @default.
• W2107580116 hasAuthorship W2107580116A5071770443 @default.
• W2107580116 hasAuthorship W2107580116A5076432829 @default.
• W2107580116 hasAuthorship W2107580116A5077015059 @default.
• W2107580116 hasAuthorship W2107580116A5078841756 @default.
• W2107580116 hasAuthorship W2107580116A5087385450 @default.
• W2107580116 hasConcept C121608353 @default.
• W2107580116 hasConcept C126322002 @default.
• W2107580116 hasConcept C141071460 @default.
• W2107580116 hasConcept C143998085 @default.
• W2107580116 hasConcept C146357865 @default.
• W2107580116 hasConcept C151730666 @default.
• W2107580116 hasConcept C2775934546 @default.
• W2107580116 hasConcept C2776694085 @default.
• W2107580116 hasConcept C2777132456 @default.
• W2107580116 hasConcept C2777658100 @default.
• W2107580116 hasConcept C2778292576 @default.
• W2107580116 hasConcept C2778822529 @default.
• W2107580116 hasConcept C2779013556 @default.
• W2107580116 hasConcept C2780964509 @default.
• W2107580116 hasConcept C3019096185 @default.
• W2107580116 hasConcept C31760486 @default.
• W2107580116 hasConcept C502942594 @default.
• W2107580116 hasConcept C530470458 @default.
• W2107580116 hasConcept C71924100 @default.
• W2107580116 hasConcept C86803240 @default.
• W2107580116 hasConcept C90924648 @default.
• W2107580116 hasConceptScore W2107580116C121608353 @default.
• W2107580116 hasConceptScore W2107580116C126322002 @default.
• W2107580116 hasConceptScore W2107580116C141071460 @default.
• W2107580116 hasConceptScore W2107580116C143998085 @default.
• W2107580116 hasConceptScore W2107580116C146357865 @default.
• W2107580116 hasConceptScore W2107580116C151730666 @default.
• W2107580116 hasConceptScore W2107580116C2775934546 @default.
• W2107580116 hasConceptScore W2107580116C2776694085 @default.
• W2107580116 hasConceptScore W2107580116C2777132456 @default.
• W2107580116 hasConceptScore W2107580116C2777658100 @default.
• W2107580116 hasConceptScore W2107580116C2778292576 @default.
• W2107580116 hasConceptScore W2107580116C2778822529 @default.
• W2107580116 hasConceptScore W2107580116C2779013556 @default.
• W2107580116 hasConceptScore W2107580116C2780964509 @default.
• W2107580116 hasConceptScore W2107580116C3019096185 @default.
• W2107580116 hasConceptScore W2107580116C31760486 @default.
• W2107580116 hasConceptScore W2107580116C502942594 @default.
• W2107580116 hasConceptScore W2107580116C530470458 @default.
• W2107580116 hasConceptScore W2107580116C71924100 @default.
• W2107580116 hasConceptScore W2107580116C86803240 @default.
• W2107580116 hasConceptScore W2107580116C90924648 @default.
• W2107580116 hasIssue "6" @default.
• W2107580116 hasLocation W21075801161 @default.

• next